Close Menu

You may find more results for this query on our sister sites: 360Dx and Precision Oncology News.

Home » Research & Discovery » Proteomics & Protein Research » Miraculins, Turning Back on Proteomics R&D, Looks to License, Acquire Dx Technologies

Miraculins, Turning Back on Proteomics R&D, Looks to License, Acquire Dx Technologies

Jun 26, 2008
Premium
Citing the high cost of research and discovery work and low return on investment, Miraculins last week announced it is moving away from the proteomics R&D field to concentrate on its diagnostics business by acquiring diagnostic technologies, making it the latest on a growing list of companies to abandon proteomics.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives

Never miss another important industry story.

Try GenomeWeb Premium now.

You may already have institutional access!

Check if I qualify.

Already a GenomeWeb or 360Dx Premium member?
Login Now.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

The Scan

European Regulators Begin Review of Sputnik V

European regulators have begun a rolling review of Russia's Sputnik V SARS-CoV-2 vaccine, Reuters reports.

Irish Funding Agency Seeks Boost

Science reports that Science Foundation Ireland is seeking annual budget increases.

Lower Fees Sought

According to the Financial Times, a UK university group is pushing Elsevier to lower its journal fees.

Nature Papers Examine Peregrine Falcon Migration Patterns, Tool to Search Single-Cell Data

In Nature this week: satellite tracking and genome sequencing combination used to examine migration patterns of peregrine falcons, and more.

Mar
11
Featured Webinar

Virtual Molecular Tumor Board Series: Gene Fusions as Druggable Targets

Sponsored by
Foundation Medicine

In this session, the third in the Precision Oncology News Virtual Molecular Tumor Board Series, our expert panelists will review patient cases in which genomic profiling has identified gene fusions that may or may not serve as druggable targets.

Mar
17
Featured Webinar

Spatial Profiling of Metabolic Regulation in the Human Tumor Microenvironment Using Multiplexed Ion Beam Imaging

Sponsored by
IONPath

In this webinar, Felix J. Hartmann of Stanford University will describe an approach that characterizes the metabolic regulome of individual cells together with their phenotypic identity.

Mar
24
Featured Webinar

Single-Cell Analysis and Genome Editing in Preclinical Disease Modeling: Detailed Insights into Leukemia Lineage

Sponsored by
Mission Bio

This webinar, the first in a “Women in Single Cell” series sponsored by Mission Bio, will discuss the use of single-cell analysis to assess genome editing for use in pre-clinical disease modeling.

Apr
20
Featured Webinar

Analysis of a Wellness Cohort Identifies Markers of Metastatic Cancer Years Prior to Diagnosis

Sponsored by
Olink

This webinar will discuss a study that sought to identify early biomarkers for cancer by analyzing pre-diagnosis samples from seemingly healthy individuals who were later diagnosed with cancer.

What's Popular?

In Proteomics & Protein Research

  1. Olink Files For Public Offering in US

  2. Complete Omics Looks to Raise New Funds, Expand Product Menu for Targeted Proteomics Tech

    Premium

  3. Waters Enters $500M Senior Notes Private Placement

  4. New Method Provides NGS-Based Readout of Glycan Levels in Single Cells

    Premium

  5. Quanterix Q4 Revenues Up 64 Percent

Sponsorships

Privacy Policy.  Terms & Conditions.  .  Copyright © 2021 GenomeWeb, a business unit of Crain Communications.  All Rights Reserved.